Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1-V3: Analysis from the MITOCARE Study.

Jia X, Heiberg E, Sejersten Ripa M, Engblom H, Carlsson M, Halvorsen S, Arheden H, Atar D, Clemmensen P, Birnbaum Y.

Cardiology. 2018 Aug 10;140(3):178-186. doi: 10.1159/000491745. [Epub ahead of print]

PMID:
30099440
2.

Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: practical perspectives based on data from the TREAT study.

Berwanger O, Abdelhamid M, Alexander T, Alzubaidi A, Averkov O, Aylward P, Contreras Zúñiga E, Halvorsen S, Iglesias R, Abdul Kader MAS, Zubaid M, AlHabib KF.

Clin Cardiol. 2018 Aug 11. doi: 10.1002/clc.23043. [Epub ahead of print]

3.

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2018 Aug 9;8(1):12107. doi: 10.1038/s41598-018-30644-x.

4.

Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial.

Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K.

ESC Heart Fail. 2018 Aug 7. doi: 10.1002/ehf2.12332. [Epub ahead of print]

PMID:
30088346
5.

Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging.

Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Ripa MS, Birnbaum Y.

J Electrocardiol. 2018 Jul - Aug;51(4):563-568. doi: 10.1016/j.jelectrocard.2018.03.016. Epub 2018 Apr 4.

PMID:
29996989
6.

The significance of ST-elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging.

Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Ripa MS, Birnbaum Y.

Ann Noninvasive Electrocardiol. 2018 Jul 4:e12580. doi: 10.1111/anec.12580. [Epub ahead of print]

PMID:
29971868
7.

Cardiovascular risk profile at the age of 40-45 in women with previous hyperemesis gravidarum or hypertensive disorders in pregnancy: A population-based study.

Fossum S, Halvorsen S, Vikanes ÅV, Roseboom TJ, Ariansen I, Næss Ø.

Pregnancy Hypertens. 2018 Apr;12:129-135. doi: 10.1016/j.preghy.2018.04.013. Epub 2018 Apr 11.

PMID:
29858105
8.

Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force.

Ibanez B, Halvorsen S, Roffi M, Bueno H, Thiele H, Vranckx P, Neumann FJ, Windecker S, James S.

Eur Heart J. 2018 May 29. doi: 10.1093/eurheartj/ehy294. [Epub ahead of print] No abstract available.

PMID:
29850788
9.

Longitudinal left ventricular function is globally depressed within a week of STEMI.

Pahlm U, Seemann F, Engblom H, Gyllenhammar T, Halvorsen S, Hansen HS, Erlinge D, Atar D, Heiberg E, Arheden H, Carlsson M.

Clin Physiol Funct Imaging. 2018 Apr 27. doi: 10.1111/cpf.12521. [Epub ahead of print]

PMID:
29701310
10.

Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction.

Hansen CH, Ritschel V, Andersen GØ, Halvorsen S, Eritsland J, Arnesen H, Seljeflot I.

Clin Appl Thromb Hemost. 2018 Jan 1:1076029618764847. doi: 10.1177/1076029618764847. [Epub ahead of print]

PMID:
29695176
11.

Correlation of ST changes in leads V4-V6 to area of ischemia by CMR in inferior STEMI.

Jia X, Heiberg E, Ripa MS, Engblom H, Halvorsen S, Arheden H, Atar D, Clemmensen P, Birnbaum Y.

Scand Cardiovasc J. 2018 Aug;52(4):189-195. doi: 10.1080/14017431.2018.1458145. Epub 2018 Mar 29.

PMID:
29595340
12.

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.

Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF.

Eur Heart J. 2018 May 14;39(19):1672-1686f. doi: 10.1093/eurheartj/ehy066. No abstract available.

PMID:
29509886
13.

[2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.]

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P.

Kardiol Pol. 2018;76(2):229-313. doi: 10.5603/KP.2018.0041. Polish. No abstract available.

14.

Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.

Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, Alexander JH.

Am Heart J. 2018 Mar;197:133-141. doi: 10.1016/j.ahj.2017.11.005. Epub 2017 Nov 10.

PMID:
29447773
15.

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.

Pol T, Held C, Westerbergh J, Lindbäck J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z.

J Am Heart Assoc. 2018 Feb 1;7(3). pii: e007444. doi: 10.1161/JAHA.117.007444.

16.

Health Economic Evaluation of Primary Prevention Strategies Against Cardiovascular Disease [Internet].

Wisløff T, Norheim OF, Halvorsen S, Selmer RM, Kristiansen IS.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Dec.

17.

Costs and Benefits from Replacing Thrombolysis with Percutaneous Coronary Intervention (PCI) [Internet].

Halvorsen S, Kristiansen IS, Linnestad K, Myhre KI, Selmer R, Wisløff T.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2004.

18.

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

Ibánez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P.

Rev Esp Cardiol (Engl Ed). 2017 Dec;70(12):1082. doi: 10.1016/j.rec.2017.11.010. English, Spanish. No abstract available.

PMID:
29198432
19.

Long-term survival in patients with acute myocardial infarction and out-of-hospital cardiac arrest: A prospective cohort study.

Kvakkestad KM, Sandvik L, Andersen GØ, Sunde K, Halvorsen S.

Resuscitation. 2018 Jan;122:41-47. doi: 10.1016/j.resuscitation.2017.11.047. Epub 2017 Nov 17.

20.

MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy.

Opstad TB, Seljeflot I, Bøhmer E, Arnesen H, Halvorsen S.

Cardiology. 2018;139(1):17-24. doi: 10.1159/000481684. Epub 2017 Nov 16.

PMID:
29141241
21.

Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.

Russo JJ, Goodman SG, Cantor WJ, Ko DT, Bagai A, Tan MK, Di Mario C, Halvorsen S, Le May M, Fernandez-Avilés F, Scheller B, Armstrong PW, Borgia F, Piscione F, Sanchez PL, Yan AT.

Am Heart J. 2017 Nov;193:46-54. doi: 10.1016/j.ahj.2017.07.015. Epub 2017 Aug 2. Review.

PMID:
29129254
22.

Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging.

Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Shah DJ, Cheong B, Sejersten M, Birnbaum Y.

J Electrocardiol. 2018 Mar - Apr;51(2):218-223. doi: 10.1016/j.jelectrocard.2017.09.013. Epub 2017 Oct 6.

PMID:
29103621
23.

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G.

J Am Coll Cardiol. 2017 Oct 3;70(14):1760-1776. doi: 10.1016/j.jacc.2017.08.037. Review.

PMID:
28958334
24.

Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction.

Ritschel V, Shetelig C, Seljeflot I, Limalanathan S, Hoffmann P, Halvorsen S, Arnesen H, Eritsland J, Andersen GØ.

Sci Rep. 2017 Sep 20;7(1):11945. doi: 10.1038/s41598-017-12372-w.

25.

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group .

Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393. No abstract available.

PMID:
28886621
26.

Editor's Choice - Acute Cardiovascular Care Association Position Paper on Intensive Cardiovascular Care Units: An update on their definition, structure, organisation and function.

Bonnefoy-Cudraz E, Bueno H, Casella G, De Maria E, Fitzsimons D, Halvorsen S, Hassager C, Iakobishvili Z, Magdy A, Marandi T, Mimoso J, Parkhomenko A, Price S, Rokyta R, Roubille F, Serpytis P, Shimony A, Stepinska J, Tint D, Trendafilova E, Tubaro M, Vrints C, Walker D, Zahger D, Zima E, Zukermann R, Lettino M.

Eur Heart J Acute Cardiovasc Care. 2018 Feb;7(1):80-95. doi: 10.1177/2048872617724269. Epub 2017 Aug 17.

PMID:
28816063
27.

Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins.

Butt N, Bache-Mathiesen LK, Nordrehaug JE, Tuseth V, Munk PS, Bonarjee V, Hall TS, Jensen SE, Halvorsen S, Firat H, Atar D, Larsen AI.

Cardiology. 2017;138(2):122-132. doi: 10.1159/000475460. Epub 2017 Jun 27.

28.

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED; TECOS Study Group.

Circulation. 2017 Sep 26;136(13):1193-1203. doi: 10.1161/CIRCULATIONAHA.117.027252. Epub 2017 Jun 16.

PMID:
28626088
29.

Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.

Lettino M, Leonardi S, De Maria E, Halvorsen S.

Eur J Prev Cardiol. 2017 Jun;24(3_suppl):61-70. doi: 10.1177/2047487317707854. Review.

PMID:
28618904
30.

Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study.

Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW.

J Am Heart Assoc. 2016 Jun 13;5(6). pii: e003559. doi: 10.1161/JAHA.116.003559.

31.

Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway.

Jortveit J, Halvorsen S.

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):132-133. doi: 10.1093/ehjcvp/pvx008. No abstract available.

PMID:
28444199
32.

Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study.

Kvakkestad KM, Wang Fagerland M, Eritsland J, Halvorsen S.

BMC Cardiovasc Disord. 2017 Mar 14;17(1):75. doi: 10.1186/s12872-017-0508-3.

33.

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2017 Mar 6;7:43941. doi: 10.1038/srep43941. Erratum in: Sci Rep. 2018 Aug 9;8(1):12107.

34.

Hyperemesis gravidarum and long-term mortality: a population-based cohort study.

Fossum S, Vikanes ÅV, Naess Ø, Vos L, Grotmol T, Halvorsen S.

BJOG. 2017 Jun;124(7):1080-1087. doi: 10.1111/1471-0528.14454. Epub 2016 Dec 15.

35.

Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients.

Chiva-Blanch G, Bratseth V, Ritschel V, Andersen GØ, Halvorsen S, Eritsland J, Arnesen H, Badimon L, Seljeflot I.

Int J Cardiol. 2017 Jan 15;227:876-881. doi: 10.1016/j.ijcard.2016.11.302. Epub 2016 Nov 27.

PMID:
27915085
36.

Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.

Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K; ESC Working Group on Thrombosis.

Eur Heart J. 2017 May 14;38(19):1455-1462. doi: 10.1093/eurheartj/ehw454. No abstract available.

PMID:
27789570
37.

A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.

Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson C.

Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. doi: 10.1093/ehjcvp/pvw031. Epub 2016 Sep 27.

38.

Gender differences in the assessment and treatment of myocardial infarction.

Jortveit J, Govatsmark RE, Langørgen J, Hole T, Mannsverk J, Olsen S, Risøe C, Halvorsen S.

Tidsskr Nor Laegeforen. 2016 Aug 23;136(14-15):1215-22. doi: 10.4045/tidsskr.16.0224. eCollection 2016 Aug. English, Norwegian.

39.

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.

Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators.

JAMA Cardiol. 2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829.

PMID:
27463942
40.

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.

JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103.

PMID:
27437883
41.

Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction.

Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland MW, Andersen GØ.

J Am Heart Assoc. 2016 Jun 13;5(6). pii: e003014. doi: 10.1161/JAHA.115.003014.

42.

Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.

Halvorsen S, Jortveit J, Hasvold P, Thuresson M, Øie E.

BMC Cardiovasc Disord. 2016 May 31;16:115. doi: 10.1186/s12872-016-0283-6.

43.

Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials.

Graham JJ, Yan AT, Tan MK, Cantor WJ, DiMario C, Jolly SS, Halvorsen S, Fernandez-Aviles F, Le May MR, Scheller B, Borgia F, Piscione F, Madan M, Goodman SG.

Cardiovasc Revasc Med. 2016 Jul-Aug;17(5):295-301. doi: 10.1016/j.carrev.2016.03.008. Epub 2016 Mar 28.

PMID:
27116940
44.

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L.

Eur Heart J. 2016 Oct 7;37(38):2869-2878. Epub 2016 Apr 12.

PMID:
27071819
45.

Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint.

Engblom H, Heiberg E, Erlinge D, Jensen SE, Nordrehaug JE, Dubois-Randé JL, Halvorsen S, Hoffmann P, Koul S, Carlsson M, Atar D, Arheden H.

J Am Heart Assoc. 2016 Mar 9;5(3):e002708. doi: 10.1161/JAHA.115.002708.

46.

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI.

Thromb Haemost. 2016 Apr;115(4):685-711. doi: 10.1160/TH15-09-0703. Epub 2016 Mar 8. Review.

PMID:
26952877
47.

Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.

Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW; STREAM Investigators.

Heart. 2016 Apr;102(7):527-33. doi: 10.1136/heartjnl-2015-308075. Epub 2016 Jan 18.

PMID:
26783237
48.

Mouse embryonic fibroblasts exhibit extensive developmental and phenotypic diversity.

Singhal PK, Sassi S, Lan L, Au P, Halvorsen SC, Fukumura D, Jain RK, Seed B.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):122-7. doi: 10.1073/pnas.1522401112. Epub 2015 Dec 22.

49.

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.

Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators.

J Am Heart Assoc. 2015 Dec 1;4(12). pii: e002015. doi: 10.1161/JAHA.115.002015.

50.

Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.

Hansen CH, Ritschel V, Halvorsen S, Andersen GØ, Bjørnerheim R, Eritsland J, Arnesen H, Seljeflot I.

Thromb J. 2015 Sep 22;13:31. doi: 10.1186/s12959-015-0061-1. eCollection 2015.

Supplemental Content

Loading ...
Support Center